Treatment as Prevention¨

Australian people living with HIV who have chosen not to take antiretrovirals and who have doubts about HIV medicine report feeling excluded and silenced within HIV organisations and communities, according to a qualitative study published online ahead of print by Medical Anthropology Quarterly. In general, the interviewees did not deny the benefits of antiretrovirals, but

John Byrne was born in 1981, a few months before the U.S. Centers for Disease Control and Prevention revealed a new report about “five young, previously healthy, gay men in Los Angeles” suffering from strange infections that had already killed two of them. That was on June 5. Throughout that summer, doctors across the United

The experts from the European Liver Patients Association (ELPA) Hep-CORE advisory group provide a great window on the diversity of hepatitis activity and perspectives in the region. In this series of short interviews, Hep-CORE PI Jeffrey Lazarus asked them how they came to work with viral hepatitis, how the field has been changing, and where

Look at the fact that the AIDS crisis is still not over — and then look at the ballot box for the 2016 presidential election. Look to the South, where young gay black men and Latinos are showing up at clinics at record rates. Look at prisons in Louisiana, look at what trans folks, trans

Un científico argentino estaría muy cerca de derrotar el virus del VIH/Sida. Se trata del Dr. Julio Montaner. Descubrió el “cóctel antirretroviral o de triple terapia”, la clave para transformar el manejo de la enfermedad. Montaner dedicó los últimos veinte años de su vida científica a investigar sobre el VIH/sida. Supo cómo sitiar al virus

The spread of hepatitis C virus (HCV) in North America peaked between 1940 and 1965, according to research published in the March 30 advance edition of Lancet Infectious Diseases. The investigators attribute the rapid spread of the infection to hospital transmissions and reuse of medical injection equipment rather than risky behaviors such as injection drugs,

The FDA has approved Descovy, a fixed-dose combination tablet containing emtricitabine and tenofovir alafenamide, for the treatment of HIV, according to the drug’s manufacturer. Descovy (emtricitabine/tenofovir alafenamide [F/TAF]; Gilead Sciences) is administered as a single oral tablet taken daily in combination with other antiretroviral agents. The formulation includes 200 mg emtricitabine and 25 mg tenofovir